Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trial
A global clinical trial, led by researchers at the Johns Hopkins Kimmel Cancer Center and its Convergence Institute, has found that adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patients with hepatocellular carcinoma, the most common type of liver cancer.
READ HERE
SEE ALL NEWS
Recent Posts
5 Healthy Habits That Help During Cancer Treatment
Understanding Mammogram Results
A 19-Year Fight Against Prostate Cancer Brings Man to Johns Hopkins Medicine
Scientists Advance Efforts to Create ‘Virtual Cell Lab’ As Testing Ground for Future Research with Live Cells
Ultra-Processed Foods: Q&A with 2 Dietitians
Radiation Therapy Overcomes Immunotherapy Resistance in Some Cancers
‘Power Surges’ on Cancer Cell Membranes May Fuel Progression of Disease
New Cancer Target Discovered
How surgeons build a new bladder for cancer patients like Deion Sanders